Sabra Healthcare (SBRA) reported $182.35 million in income for the quarter ended December 2024, representing a year-over-year enhance of 11.6%. EPS of $0.36 for a similar interval compares to $0.07 a yr in the past.
The reported income compares to the Zacks Consensus Estimate of $183.22 million, representing a shock of -0.48%. The corporate has not delivered EPS shock, with the consensus EPS estimate being $0.36.
Whereas traders carefully watch year-over-year adjustments in headline numbers — income and earnings — and the way they examine to Wall Avenue expectations to find out their subsequent plan of action, some key metrics at all times present a greater perception into an organization’s underlying efficiency.
Since these metrics play an important position in driving the top- and bottom-line numbers, evaluating them with the year-ago numbers and what analysts estimated about them helps traders higher mission a inventory’s value efficiency.
Right here is how Sabra carried out within the simply reported quarter by way of the metrics most generally monitored and projected by Wall Avenue analysts:
- Revenues- Curiosity and different revenue: $9.41 million in comparison with the $9.71 million common estimate based mostly on three analysts. The reported quantity represents a change of +3.4% yr over yr.
- Revenues- Resident charges and providers: $76.87 million versus $75.05 million estimated by two analysts on common. In comparison with the year-ago quarter, this quantity represents a +25.5% change.
- Revenues- Rental and associated revenues: $96.07 million versus the two-analyst common estimate of $96.34 million. The reported quantity represents a year-over-year change of +3.3%.
- Internet Earnings Per Share (Diluted): $0.19 versus $0.16 estimated by three analysts on common.
View all Key Company Metrics for Sabra here>>>
Shares of Sabra have returned -3.5% over the previous month versus the Zacks S&P 500 composite’s +2.4% change. The inventory presently has a Zacks Rank #2 (Purchase), indicating that it may outperform the broader market within the close to time period.
Zacks’ Analysis Chief Names “Inventory Most Prone to Double”
Our workforce of consultants has simply launched the 5 shares with the best likelihood of gaining +100% or extra within the coming months. Of these 5, Director of Analysis Sheraz Mian highlights the one inventory set to climb highest.
This prime choose is among the many most modern monetary companies. With a fast-growing buyer base (already 50+ million) and a various set of leading edge options, this inventory is poised for giant positive aspects. In fact, all our elite picks aren’t winners however this one may far surpass earlier Zacks’ Shares Set to Double like Nano-X Imaging which shot up +129.6% in little greater than 9 months.
Free: See Our Top Stock And 4 Runners Up
Sabra Healthcare REIT, Inc. (SBRA) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the creator and don’t essentially replicate these of Nasdaq, Inc.
